COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

被引：0
|
作者：
Su, W. [1 ]
Rengarajan, B. [2 ]
Profant, D. [2 ]
Mayo, K. [1 ]
Groff, M. [3 ]
Tremblay, G. [3 ]
Ganti, A. K. [4 ]
机构：
[1] Jazz Pharmaceut, Philadelphia, PA USA
[2] Jazz Pharmaceut, Palo Alto, CA USA
[3] Cytel Inc, Cambridge, MA USA
[4] VA Nebraska Iowa Hlth Care Syst, Omaha, NE USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE152
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [1] Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).
    Forster, Martin
    Calvo, Emiliano
    Olmedo Garcia, Maria Eugenia
    Pilar Lopez Criado, M.
    Moreno, Victor
    Soto-Matos, Arturo
    Holgado, Esther
    Brown, Nicholas F.
    Flynn, Michael
    Boni, Valentina
    Guerra Alia, Eva
    Szyldergemajn, Sergio A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Cheng, Ying
    Wu, Chunjiao
    Wu, Lin
    Zhao, Jun
    Zhao, Yanqiu
    Chen, Lulu
    Xin, Ying
    Zhang, Liang
    Pan, Pinhua
    Li, Xingya
    Li, Juan
    Dong, Xiaorong
    Tang, Ke
    Gao, Emei
    Yu, Fei
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [3] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Ying Cheng
    Chunjiao Wu
    Lin Wu
    Jun Zhao
    Yanqiu Zhao
    Lulu Chen
    Ying Xin
    Liang Zhang
    Pinhua Pan
    Xingya Li
    Juan Li
    Xiaorong Dong
    Ke Tang
    Emei Gao
    Fei Yu
    Scientific Reports, 14
  • [4] SCLC: second-line therapy with lurbinectedin and doxorubicin on trial
    Simon, Annika
    PNEUMOLOGIE, 2023, 77 (10):
  • [5] Zweitlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)Second-line therapy for small cell lung cancer (SCLC)
    F. Griesinger
    T. Overbeck
    N. Niederle
    Der Onkologe, 2005, 11 (7): : 730 - 740
  • [6] Second-line chemotherapy for small-Cell Lung Cancer (SCLC)
    Kim, Young Hak
    Mishima, Michiaki
    CANCER TREATMENT REVIEWS, 2011, 37 (02) : 143 - 150
  • [7] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [8] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    PharmacoEconomics, 2004, 22 : 581 - 589
  • [9] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [10] Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin
    Estrin, A.
    Wang, X.
    Boccuti, A.
    Prince, P.
    Gautam, N.
    Rengarajan, B.
    Li, W.
    Lu, T.
    Cao, Y.
    Naveh, N.
    D'Agostino, R.
    Ben-Joseph, R.
    Ganti, A. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1250 - S1250
12345